Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90-minute obinutuzumab infusion in chronic lymphocytic leukemia or follicular lymphoma
ACTRN12624001142527Phase 4Not yet recruiting
- Sponsor
- Cairns Hospital
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of obinutuzumab in follicular lymphoma (FL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Cairns Hospital. Primary endpoint: Rate of infusion reactions. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
obinutuzumab
03
Conditions
follicular lymphoma (FL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on ACTRN12624001142527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001142527.